Gene:
TARDBP
TAR DNA binding protein

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  ALS10; TDP-43
PharmGKB Accession Id: PA36336

Details

Cytogenetic Location: chr1 : p36.22 - p36.22
GP mRNA Boundary: chr1 : 11072679 - 11085549
GP Gene Boundary: chr1 : 11062679 - 11088549
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to TARDBP: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (New York, N.Y.). 2008. Sreedharan Jemeen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (New York, N.Y.). 2006. Neumann Manuela, et al. PubMed

LinkOuts

Entrez Gene:
23435
OMIM:
605078
612069
UCSC Genome Browser:
NM_007375
RefSeq RNA:
NM_007375
RefSeq Protein:
NP_031401
RefSeq DNA:
AC_000044
AC_000133
NC_000001
NG_008734
NT_021937
NW_001838534
NW_923572
UniProtKB:
A4GUK5_HUMAN (A4GUK5)
TADBP_HUMAN (Q13148)
Ensembl:
ENSG00000120948
GenAtlas:
TARDBP
GeneCard:
TARDBP
MutDB:
TARDBP
ALFRED:
LO100343L
HuGE:
TARDBP
Comparative Toxicogenomics Database:
23435
ModBase:
Q13148
HumanCyc Gene:
HS04455
HGNC:
11571

Common Searches